Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats

Neuropsychopharmacology

Volumn 37, Issue 10, 2012, Pages 2310-2321

  Hopkins, Thomas J ^a   Rupprecht, Laura E ^a   Hayes, Matthew R ^a   Blendy, Julie A ^a   Schmidt, Heath D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

acetylcholine; nicotine addiction; nicotinic receptors; relapse; smoking cessation

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; MECAMYLAMINE; NICOTINE; NICOTINIC RECEPTOR; SUCROSE;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; FOOD INTAKE; MALE; NONHUMAN; PICA; PRIORITY JOURNAL; RAT; REINFORCEMENT; RELAPSE; SMOKING CESSATION; TOBACCO DEPENDENCE;

ALLOSTERIC REGULATION; ANIMALS; CHOLINESTERASE INHIBITORS; DRUG-SEEKING BEHAVIOR; EXTINCTION, PSYCHOLOGICAL; GALANTAMINE; MALE; NICOTINE; RATS; RECEPTORS, NICOTINIC; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 84865215619     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.83     Document Type: Article

References (88)

1. Andreoli M, Tessari M, Pilla M, Valerio E, Hagan JJ, Heidbreder CA (2003). Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 28: 1272-1280. (Pubitemid 41070897)
2. Andrews PL, Horn CC (2006). Signals for nausea and emesis: implications for models of upper gastrointestinal diseases. Auton Neurosci 125: 100-115.
3. Atzori G, Lemmonds CA, Kotler ML, Durcan MJ, Boyle J (2008). Efficacy of a nicotine (4 mg)-containing lozenge on the cognitive impairment of nicotine withdrawal. J Clin Psychopharmacol 28: 667-674.
4. Baker RR, Massey ED, Smith G (2004). An overview of the effects of tobacco ingredients on smoke chemistry and toxicity. Food Chem Toxicol 42(Suppl): S53-S83. (Pubitemid 38456980)
5. Barnes CA, Meltzer J, Houston F, Orr G, McGann K, Wenk GL (2000). Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99: 17-23. (Pubitemid 30495548)
6. Benowitz NL (2010). Nicotine addiction. N Engl J Med 362: 2295-2303.
7. Bespalov AY, Dravolina OA, Sukhanov I, Zakharova E, Blokhina E, Zvartau E et al (2005). Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and scheduleinduced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology 49(Suppl 1): 167-178. (Pubitemid 41115903)
8. Bickel U, Thomsen T, Weber W, Fischer JP, Bachus R, Nitz M et al (1991). Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin PharmacolTher 50: 420-428.
9. Camacho F, Smith CP, Vargas HM, Winslow JT (1996). Alpha 2- adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology 124: 347-354.
10. Changeux JP (2010). Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat Rev Neurosci 11: 389-401.
11. Chaudhri N, Caggiula AR, Donny EC, Booth S, Gharib M, Craven L et al (2006). Operant responding for conditioned and unconditioned reinforcers in rats is differentially enhanced by the primary reinforcing and reinforcement- enhancing effects of nicotine. Psychopharmacology 189: 27-36. (Pubitemid 44607257)
12. Corrigall WA (1999). Nicotine self-administration in animals as a dependence model. Nicotine Tob Res 1: 11-20.
13. Corrigall WA, Coen KM (1989). Nicotine maintains robust selfadministration in rats on a limited-access schedule. Psychopharmacology 99: 473-478. (Pubitemid 19273101)
14. Davis JA, James JR, Siegel SJ, Gould TJ (2005). Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. J Neurosci 25: 8708-8713. (Pubitemid 41362049)
15. De Biasi M, Dani JA (2011). Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci 34: 105-130.
16. De Jonghe BC, Lawler MP, Horn CC, Tordoff MG (2009). Pica as an adaptive response: Kaolin consumption helps rats recover from chemotherapy-induced illness. Physiol Behav 97: 87-90.
17. Diehl A, Nakovics H, Croissant B, Smolka MN, Batra A, Mann K (2006). Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial. Int J Clin Pharmacol Ther 44: 614-622. (Pubitemid 44896139)
18. Diehl A, Nakovics H, Mutschler J, Hermann D, Kiefer F (2009). Rivastigmine reduces tobacco craving in alcohol-dependent smokers. Pharmacopsychiatry 42: 89-94.
19. Donny EC, Caggiula AR, Mielke MM, Booth S, Gharib MA, Hoffman A et al (1999). Nicotine self-administration in rats on a progressive ratio schedule of reinforcement. Psychopharmacology 147: 135-142. (Pubitemid 30010560)
20. Dunbar F, Zhu Y, Brashear HR (2006). Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallelgroup, 6-month study. Clin Ther 28: 365-372. (Pubitemid 43783439)
21. Epping-Jordan MP, Picciotto MR, Changeux JP, Pich EM (1999). Assessment of nicotinic acetylcholine receptor subunit contributions to nicotine self-administration in mutant mice. Psychopharmacology 147: 25-26. (Pubitemid 30010017)
22. Evans WE, Yee GC, Crom WR, Pratt CB, Green AA (1981). Clinical pharmacology of bleomycin and cisplatin. Head Neck Surg 4: 98-110. (Pubitemid 12247745)
23. Feltenstein MW, Ghee SM, See RE (2012). Nicotine self-administration and reinstatement of nicotine-seeking in male and female rats. Drug Alcohol Depend 121: 240-246.
24. Fowler CD, Kenny PJ (2011). Intravenous nicotine self-administration and cue-induced reinstatement in mice: effects of nicotine dose, rate of drug infusion and prior instrumental training. Neuropharmacology 61: 687-698.
25. Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ (2011). Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature 471: 597-601.
26. George O, Lloyd A, Carroll FI, Damaj MI, Koob GF (2011). Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration. Psychopharmacology 213: 715-722.
27. Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T et al (2010). Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-Daspartate receptor antagonism. J Pharmacol Exp Ther 333: 748-757.
28. Gould TJ, Feiro OR (2005). Age-related deficits in the retention of memories for cued fear conditioning are reversed by galantamine treatment. Behav Brain Res 165: 160-171. (Pubitemid 41565526)
29. Grenhoff J, Aston-Jones G, Svensson TH (1986). Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 128: 351-358. (Pubitemid 17182735)
30. Harvey AL (1995). The pharmacology of galanthamine and its analogues. Pharmacol Ther 68: 113-128.
31. Hernandez CM, Gearhart DA, Parikh V, Hohnadel EJ, Davis LW, Middlemore ML et al (2006). Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. J Pharmacol Exp Ther 316: 679-694. (Pubitemid 43130995)
32. Hughes JR, Hatsukami D (1986). Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43: 289-294. (Pubitemid 16052281)
33. Jackisch R, Forster S, Kammerer M, Rothmaier AK, Ehret A, Zentner J et al (2009). Inhibitory potency of choline esterase inhibitors on acetylcholine release and choline esterase activity in fresh specimens of human and rat neocortex. J Alzheimers Dis 16: 635-647.
34. Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR (2012). The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 62: 1916-1927.
35. Kelly DL, McMahon RP, Weiner E, Boggs DL, Dickinson D, Conley RR et al (2008). Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia. Schizophr Res 103: 161-168.
36. Kenny PJ, Markou A (2001). Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav 70: 531-549. (Pubitemid 34131647)
37. Lerman C, LeSage MG, Perkins KA, O'Malley SS, Siegel SJ, Benowitz NL et al (2007). Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 6: 746-762. (Pubitemid 47338182)
38. Liu YL, Malik N, Sanger GJ, Friedman MI, Andrews PL (2005). Pica-a model of nausea? Species differences in response to cisplatin. Physiol Behav 85: 271-277. (Pubitemid 40840743)
39. Lynch WJ, Carroll ME (1999). Regulation of intravenously self-administered nicotine in rats. Exp Clin Psychopharmacol 7: 198-207. (Pubitemid 29399022)
40. Lynch WJ, Carroll ME (2001). Regulation of drug intake. Exp Clin Psychopharmacol 9: 131-143. (Pubitemid 32852310)
41. Maelicke A, Albuquerque EX (2000). Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393: 165-170. (Pubitemid 30193413)
42. Mansvelder HD, Keath JR, McGehee DS (2002). Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33: 905-919. (Pubitemid 34246356)
43. Mansvelder HD, McGehee DS (2000). Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27: 349-357.
44. Marcos B, Chuang TT, Gil-Bea FJ, Ramirez MJ (2008). Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br J Pharmacol 155: 434-440.
45. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP et al (2005). Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436: 103-107. (Pubitemid 40966193)
46. Mathieu-Kia AM, Kellogg SH, Butelman ER, Kreek MJ (2002). Nicotine addiction: insights from recent animal studies. Psychopharmacology 162: 102-118. (Pubitemid 34743950)
47. Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR et al (2007). Guidelines on nicotine dose selection for in vivo research. Psychopharmacology 190: 269-319. (Pubitemid 46156883)
48. Mitchell D, Wells C, Hoch N, Lind K, Woods SC, Mitchell LK (1976). Poison induced pica in rats. Physiol Behav 17: 691-697. (Pubitemid 8004084)
49. Myers CS, Taylor RC, Moolchan ET, Heishman SJ (2008). Doserelated enhancement of mood and cognition in smokers administered nicotine nasal spray. Neuropsychopharmacology 33: 588-598.
50. O'Connor EC, Parker D, Rollema H, Mead AN (2010). The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology 208: 365-376.
51. Palmatier MI, Evans-Martin FF, Hoffman A, Caggiula AR, Chaudhri N, Donny EC et al (2006). Dissociating the primary reinforcing and reinforcement- enhancing effects of nicotine using a rat self-administration paradigm with concurrently available drug and environmental reinforcers. Psychopharmacology 184: 391-400. (Pubitemid 43255855)
52. Palmatier MI, Matteson GL, Black JJ, Liu X, Caggiula AR, Craven L et al (2007). The reinforcement enhancing effects of nicotine depend on the incentive value of non-drug reinforcers and increase with repeated drug injections. Drug Alcohol Depend 89: 52-59. (Pubitemid 46604860)
53. Patterson F, Jepson C, Loughead J, Perkins K, Strasser AA, Siegel S et al (2010). Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend 106: 61-64.
54. Pepeu G, Giovannini MG (2009). Cholinesterase inhibitors and beyond. Curr Alzheimer Res 6: 86-96.
55. Picciotto MR (2003). Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci 24: 493-499. (Pubitemid 37088175)
56. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM et al (1998). Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391: 173-177. (Pubitemid 28092475)
57. Prvulovic D, Hampel H, Pantel J (2010). Galantamine for Alzheimer's disease. Expert Opin Drug Metab Toxicol 6: 345-354.
58. Raskind MA, Peskind ER, Wessel T, Yuan W (2000). Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54: 2261-2268. (Pubitemid 30416276)
59. Rauhut AS, Mullins SN, Dwoskin LP, Bardo MT (2002). Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Ther 303: 664-672. (Pubitemid 35231239)
60. Raybuck JD, Portugal GS, Lerman C, Gould TJ (2008). Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. Behav Neurosci 122: 1166-1171.
61. Rose JE, Corrigall WA (1997). Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology 130: 28-40. (Pubitemid 27107782)
62. Rukstalis M, Jepson C, Patterson F, Lerman C (2005). Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy. J Subst Abuse Treat 28: 297-304. (Pubitemid 40733138)
63. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C et al (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305: 1024-1036. (Pubitemid 36617980)
64. Schilstrom B, Fagerquist MV, Zhang X, Hertel P, Panagis G, Nomikos GG et al (2000). Putative role of presynaptic alpha7 nicotinic receptors in nicotine stimulated increases of extracellular levels of glutamate and aspartate in the ventral tegmental area. Synapse 38: 375-383.
65. Schilstrom B, Ivanov VB, Wiker C, Svensson TH (2007). Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 32: 43-53. (Pubitemid 44967783)
66. Schilstrom B, Rawal N, Mameli-Engvall M, Nomikos GG, Svensson TH (2003). Dual effects of nicotine on dopamine neurons mediated by different nicotinic receptor subtypes. Int J Neuropsychopharmacol 6: 1-11. (Pubitemid 36373095)
67. Schilstrom B, Svensson HM, Svensson TH, Nomikos GG (1998). Nicotine and food induced dopamine release in the nucleus accumbens of the rat: putative role of alpha7 nicotinic receptors in the ventral tegmental area. Neuroscience 85: 1005-1009. (Pubitemid 28293408)
68. Schmidt HD, Anderson SM, Famous KR, Kumaresan V, Pierce RC (2005). Anatomy and pharmacology of cocaine priming-induced reinstatement of drug seeking. Eur J Pharmacol 526: 65-76. (Pubitemid 41744106)
69. Schmidt HD, Pierce RC (2010). Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction. Ann NY Acad Sci 1187: 35-75.
70. Schnoll RA, Lerman C (2006). Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs 11: 429-444. (Pubitemid 44386368)
71. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A (1996). Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49: 1-6. (Pubitemid 26036779)
72. Shaham Y, Adamson LK, Grocki S, Corrigall WA (1997). Reinstatement and spontaneous recovery of nicotine seeking in rats. Psychopharmacology 130: 396-403. (Pubitemid 27179734)
73. Shalev U, Grimm JW, Shaham Y (2002). Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 54: 1-42. (Pubitemid 34208828)
74. Sharp BM, Yatsula M, Fu Y (2004). Effects of galantamine, a nicotinic allosteric potentiating ligand, on nicotine-induced catecholamine release in hippocampus and nucleus accumbens of rats. J Pharmacol Exp Ther 309: 1116-1123. (Pubitemid 38669699)
75. Shoaib M, Schindler CW, Goldberg SR (1997). Nicotine selfadministration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology 129: 35-43. (Pubitemid 27037448)
76. Smulders CJ, Zwart R, Bermudez I, van Kleef RG, Groot-Kormelink PJ, Vijverberg HP (2005). Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol 509: 97-108. (Pubitemid 40279067)
77. Sofuoglu M, Waters AJ, Poling J, Carroll KM (2011). Galantamine improves sustained attention in chronic cocaine users. Exp Clin Psychopharmacol 19: 11-19.
78. Spealman RD, Goldberg SR (1982). Maintenance of schedulecontrolled behavior by intravenous injections of nicotine in squirrel monkeys. J Pharmacol Exp Ther 223: 402-408. (Pubitemid 12005740)
79. Sweeney JE, Bachman ES, Coyle JT (1990). Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice. Psychopharmacology 102: 191-200. (Pubitemid 20264658)
80. Sweeney JE, Hohmann CF, Moran TH, Coyle JT (1988). A longacting cholinesterase inhibitor reverses spatial memory deficits in mice. Pharmacol Biochem Behav 31: 141-147. (Pubitemid 19271195)
81. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54: 2269-2276.
82. Tuesta LM, Fowler CD, Kenny PJ (2011). Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior. Biochem Pharmacol 82: 984-995.
83. Villarroya M, Garcia AG, Marco-Contelles J, Lopez MG (2007). An update on the pharmacology of galantamine. Expert Opin Investig Drugs 16: 1987-1998. (Pubitemid 351403729)
84. Watkins SS, Epping-Jordan MP, Koob GF, Markou A (1999). Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 62: 743-751. (Pubitemid 29127180)
85. Wilkinson DS, Gould TJ (2011). The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice. Behav Brain Res 223: 53-57.
86. Woodruff-Pak DS, Lander C, Geerts H (2002). Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev 8: 405-426. (Pubitemid 36114720)
87. Yamamoto K, Matsunaga S, Matsui M, Takeda N, Yamatodani A (2002). Pica in mice as a new model for the study of emesis. Methods Find Exp Clin Pharmacol 24: 135-138. (Pubitemid 34534589)
88. Yan Y, Pushparaj A, Le Strat Y, Gamaleddin I, Barnes C, Justinova Z et al (2012). Blockade of dopamine D4 receptors attenuates reinstatement of extinguished nicotine-seeking behavior in rats. Neuropsychopharmacology 37: 685-696.